Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Bliss GVS Pharma has informed that a meeting of the Board of Directors of the Company will be held on Thursday, November 06, 2025 at the registered office of the Company to consider and approve, the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2025. Further, according to SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company’s Code of Internal Procedures and Conduct for Regulating, Monitoring, and Reporting of Trading by Designated Persons, the trading window for dealing in shares of the Company was closed for all the Designated Persons and their immediate relatives of the Company from October 01, 2025, and shall remain closed till 48 hours after the announcement/declaration of Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2025. This intimation is also being uploaded on the Company's website at http://www.blissgvs.com/.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1654.70 |
| Dr. Reddys Lab | 1232.00 |
| Cipla | 1229.60 |
| Zydus Lifesciences | 915.45 |
| Lupin | 2332.70 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: